scPharmaceuticals Inc. (NASDAQ:SCPH – Get Free Report) was the recipient of a large increase in short interest in June. As of June 15th, there was short interest totalling 5,780,000 shares, an increase of 19.9% from the May 31st total of 4,820,000 shares. Based on an average daily trading volume, of 237,500 shares, the days-to-cover ratio is currently 24.3 days. Approximately 26.5% of the shares of the company are sold short.
Institutional Trading of scPharmaceuticals
A number of institutional investors and hedge funds have recently modified their holdings of SCPH. Rubric Capital Management LP grew its holdings in scPharmaceuticals by 29.0% during the fourth quarter. Rubric Capital Management LP now owns 3,500,000 shares of the company’s stock valued at $21,945,000 after purchasing an additional 786,713 shares during the period. Worth Venture Partners LLC lifted its holdings in scPharmaceuticals by 42.9% during the fourth quarter. Worth Venture Partners LLC now owns 771,344 shares of the company’s stock valued at $4,836,000 after purchasing an additional 231,679 shares during the last quarter. AIGH Capital Management LLC increased its stake in shares of scPharmaceuticals by 40.8% in the fourth quarter. AIGH Capital Management LLC now owns 3,106,795 shares of the company’s stock worth $19,480,000 after purchasing an additional 899,786 shares in the last quarter. King Luther Capital Management Corp raised its position in shares of scPharmaceuticals by 48.8% in the fourth quarter. King Luther Capital Management Corp now owns 1,393,525 shares of the company’s stock valued at $8,737,000 after purchasing an additional 457,150 shares during the period. Finally, IPG Investment Advisors LLC purchased a new stake in shares of scPharmaceuticals during the 4th quarter valued at approximately $75,000. 89.52% of the stock is owned by hedge funds and other institutional investors.
scPharmaceuticals Stock Down 0.7 %
Shares of scPharmaceuticals stock opened at $4.32 on Tuesday. The stock’s 50-day moving average is $4.22 and its 200 day moving average is $5.08. The firm has a market cap of $155.74 million, a price-to-earnings ratio of -2.92 and a beta of 0.12. The company has a debt-to-equity ratio of 1.60, a current ratio of 6.21 and a quick ratio of 5.44. scPharmaceuticals has a one year low of $3.24 and a one year high of $10.09.
Analyst Ratings Changes
Separately, HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of scPharmaceuticals in a research note on Wednesday, May 15th.
View Our Latest Report on SCPH
About scPharmaceuticals
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.
See Also
- Five stocks we like better than scPharmaceuticals
- Market Cap Calculator: How to Calculate Market Cap
- The Top 4 Magnificent 7 Stocks to Buy in the Year’s Second Half
- The How And Why of Investing in Oil Stocks
- Steel Dynamics Stock is Up 9.6% While Its Peers Are Rusting
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Snowflake Stock Rebounds, Flies Higher on AI Spending
Receive News & Ratings for scPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for scPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.